EE03856B1 - Erütropoetiini ja rauapreparaatide kasutamine farmatseutilise liitpreparaadi valmistamiseks, farmatseutiline ühispakend ja meetod rauaseisundi määramiseks kehavedelike proovis - Google Patents

Erütropoetiini ja rauapreparaatide kasutamine farmatseutilise liitpreparaadi valmistamiseks, farmatseutiline ühispakend ja meetod rauaseisundi määramiseks kehavedelike proovis

Info

Publication number
EE03856B1
EE03856B1 EE9800066A EE9800066A EE03856B1 EE 03856 B1 EE03856 B1 EE 03856B1 EE 9800066 A EE9800066 A EE 9800066A EE 9800066 A EE9800066 A EE 9800066A EE 03856 B1 EE03856 B1 EE 03856B1
Authority
EE
Estonia
Prior art keywords
preparation
iron
pharmaceutical
erythropoietin
sample
Prior art date
Application number
EE9800066A
Other languages
English (en)
Estonian (et)
Other versions
EE9800066A (et
Inventor
Lehmann Paul
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of EE9800066A publication Critical patent/EE9800066A/xx
Publication of EE03856B1 publication Critical patent/EE03856B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EE9800066A 1995-09-14 1996-09-12 Erütropoetiini ja rauapreparaatide kasutamine farmatseutilise liitpreparaadi valmistamiseks, farmatseutiline ühispakend ja meetod rauaseisundi määramiseks kehavedelike proovis EE03856B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19535571A DE19535571A1 (de) 1995-09-14 1995-09-14 Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten
PCT/EP1996/003997 WO1997009996A1 (de) 1995-09-14 1996-09-12 Pharmazeutische kombinationspräparate enthaltend erythropoietin und eisenpräparate

Publications (2)

Publication Number Publication Date
EE9800066A EE9800066A (et) 1998-08-17
EE03856B1 true EE03856B1 (et) 2002-10-15

Family

ID=7773098

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800066A EE03856B1 (et) 1995-09-14 1996-09-12 Erütropoetiini ja rauapreparaatide kasutamine farmatseutilise liitpreparaadi valmistamiseks, farmatseutiline ühispakend ja meetod rauaseisundi määramiseks kehavedelike proovis

Country Status (26)

Country Link
US (2) US6333306B1 (xx)
EP (1) EP0851762B1 (xx)
JP (1) JP4783482B2 (xx)
KR (1) KR100350761B1 (xx)
CN (1) CN1133463C (xx)
AT (1) ATE216256T1 (xx)
AU (1) AU724623B2 (xx)
BR (1) BR9609971A (xx)
CA (1) CA2231192C (xx)
CZ (1) CZ291427B6 (xx)
DE (3) DE19535571A1 (xx)
DK (1) DK0851762T3 (xx)
EE (1) EE03856B1 (xx)
ES (1) ES2174107T3 (xx)
HU (1) HU225363B1 (xx)
IL (2) IL123640A0 (xx)
MX (1) MX9801922A (xx)
NO (1) NO329908B1 (xx)
NZ (1) NZ319132A (xx)
PL (1) PL186776B1 (xx)
PT (1) PT851762E (xx)
SK (1) SK285796B6 (xx)
TR (1) TR199800472T1 (xx)
UA (1) UA57713C2 (xx)
WO (1) WO1997009996A1 (xx)
ZA (1) ZA967732B (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998041226A1 (de) * 1997-03-18 1998-09-24 Roche Diagnostics Gmbh Pharmazeutische kombinationspräparate enthaltend erythropoietin und eisenpräparate
EP0885613A1 (de) * 1997-06-21 1998-12-23 Roche Diagnostics GmbH Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin
DE19734293A1 (de) * 1997-08-08 1999-02-11 Boehringer Mannheim Gmbh Verwendung von pharmazeutischen Kombinationspräparaten enthaltend Erythropoietin und Eisenpräparate zur Behandlung von rheumatischen Erkrankungen
DK1813624T3 (da) * 1998-10-23 2010-11-22 Amgen Inc Fremgangsmåder og sammensætninger til forebyggelse og behandling af anæmi
US7304150B1 (en) 1998-10-23 2007-12-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
CA2431964C (en) 2000-12-20 2013-09-10 F. Hoffmann-La Roche Ag Conjugates of erythropoietin (pep) with polyethylene glycol (peg)
EP1909106B1 (en) * 2001-09-14 2013-01-02 F. Hoffmann-La Roche AG Differential diagnosis of disorders of iron metabolism by means of four parameters and recommendations for the treatment of these disorders of iron metabolism
US6930086B2 (en) 2001-09-25 2005-08-16 Hoffmann-La Roche Inc. Diglycosylated erythropoietin
US7300915B2 (en) * 2002-06-05 2007-11-27 The Regents Of The University Of California Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain
US7459435B2 (en) * 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US7459436B2 (en) 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US7964568B2 (en) * 2003-05-30 2011-06-21 Chromaceutical Advanced Technologies, Inc. Synthesis of high molecular weight iron-saccharidic complexes
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US7586589B2 (en) * 2005-09-24 2009-09-08 Beckman Coulter, Inc. Methods of determination of responsiveness to erythropoietin treatment
ES2529234T3 (es) 2006-08-04 2015-02-18 Prolong Pharmaceuticals, LLC Eritropoyetina modificada
CL2008002053A1 (es) 2007-07-17 2009-05-22 Hoffmann La Roche Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
AR067536A1 (es) 2007-07-17 2009-10-14 Hoffmann La Roche Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea
NZ753905A (en) 2013-06-13 2020-07-31 Akebia Therapeutics Inc Compositions and methods for treating anemia
EP3789395A1 (en) 2015-11-23 2021-03-10 Bristol-Myers Squibb Company Pegylation of fgf21

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6039681B2 (ja) * 1976-01-01 1985-09-07 日本臓器製薬株式会社 デキストリン・クエン酸・第二鉄多核複合体及び該複合体を含有する非経口用鉄剤
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst AND sequence encoding human erythropoietin, a process for its preparation and a pharmacological preparation of human erythropoietin
US4745099A (en) * 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
JPS6231A (ja) * 1985-02-06 1987-01-06 Chugai Pharmaceut Co Ltd 腎性貧血治療剤
JP2858752B2 (ja) * 1987-04-10 1999-02-17 オーソ・フアーマシユーチカル・コーポレーシヨン 正常な哺乳動物のヘマトクリツト値の増大方法

Also Published As

Publication number Publication date
BR9609971A (pt) 1999-09-14
HUP9900357A2 (hu) 1999-05-28
CZ291427B6 (cs) 2003-03-12
JP4783482B2 (ja) 2011-09-28
UA57713C2 (uk) 2003-07-15
EE9800066A (et) 1998-08-17
DE19535571A1 (de) 1997-03-20
AU7128296A (en) 1997-04-01
MX9801922A (es) 1998-05-31
US20020049161A1 (en) 2002-04-25
DK0851762T3 (da) 2002-08-12
NZ319132A (en) 1999-09-29
CN1202113A (zh) 1998-12-16
IL123640A (en) 2006-06-11
NO981136L (no) 1998-03-13
IL123640A0 (en) 1998-10-30
HUP9900357A3 (en) 2001-04-28
EP0851762B1 (de) 2002-04-17
NO981136D0 (no) 1998-03-13
TR199800472T1 (xx) 1998-06-22
AU724623B2 (en) 2000-09-28
US6333306B1 (en) 2001-12-25
DE19680768D2 (de) 1998-11-05
CA2231192C (en) 2003-02-25
EP0851762A1 (de) 1998-07-08
PL186776B1 (pl) 2004-02-27
ATE216256T1 (de) 2002-05-15
WO1997009996A1 (de) 1997-03-20
SK285796B6 (sk) 2007-08-02
SK32798A3 (en) 1999-03-12
DE59609099D1 (de) 2002-05-23
PT851762E (pt) 2002-08-30
CN1133463C (zh) 2004-01-07
PL325640A1 (en) 1998-08-03
ES2174107T3 (es) 2002-11-01
NO329908B1 (no) 2011-01-24
ZA967732B (en) 1998-03-13
HU225363B1 (en) 2006-10-28
JPH11512414A (ja) 1999-10-26
CA2231192A1 (en) 1997-03-20
KR19990044610A (ko) 1999-06-25
CZ72698A3 (cs) 1998-07-15
KR100350761B1 (ko) 2003-03-03

Similar Documents

Publication Publication Date Title
EE03856B1 (et) Erütropoetiini ja rauapreparaatide kasutamine farmatseutilise liitpreparaadi valmistamiseks, farmatseutiline ühispakend ja meetod rauaseisundi määramiseks kehavedelike proovis
NZ266475A (en) Use of recombinant adenovirus of animal origin in making pharmaceutical composition
CA2099400A1 (en) Reliable noninvasive measurement of blood gases
HU9602937D0 (en) Compositions comprising dna damaging agents and p53
FI972287A (fi) Uudenlaisia polysubstituoituja DTPA-johdoksia ja niiden metallikomplekseja, kyseisiä komplekseja sisältäviä farmaseuttisia aineita, niiden käyttö diagnosoinnissa ja terapiassa sekä menetelmiä kyseisten kompleksinmuodostajien ja kompleksien valmistamiseksi ja menetelmiä kyseisten.
CZ285522B6 (cs) Farmaceutický prostředek pro snížení koncentrace glukosy v krvi
HUT78092A (hu) P277 Peptidanalógok és ezeket tartalmazó gyógyszerkészítmények a diabétesz kezelésére vagy diagnosztizálására
DK0996462T3 (da) Farmaceutiske kombinationspræparater indeholdende erythropoietin og modificerede hæmoglobiner
DE59707988D1 (de) Pharmazeutische kombinationspräparate enthaltend erythropoietin und eisenpräparate
HU902004D0 (en) New trombolitic preparations
CA2127107A1 (en) Methods and compositions for reducing blood loss
TWI263502B (en) Pharmaceutical preparation for treating ischemic disease of heart or limbs
EP0351790A3 (de) Verfahren zur Bestimmung von Fructosamin
GEP20012377B (en) Use of Trophoblastic Beta-1 Glycoprotein for Treating Auto-Immune Diseases and Method of Treatment These Diseases
TR199902305T2 (xx) Eritropoitein ve demir preperasyonları içeren farmasötik birleşimli preperasyonlar.
PT999849E (pt) Utilizacao de lbp no tratamento da septicemia
UA5743C2 (uk) Препарат тканинних біологічно активних речовин, який має регенаторну дію, та спосіб його одержання
UA9703A (uk) Антипротеіназний засіб
UA19647A (uk) Спосіб лікуваhhя остеомієліту щелепи
GEU1999444Y (en) Medicinal Means “Barambo”
MX9703032A (es) Nuevas aplicaciones del 5-etoxicarbonil-2,4,6-trimetil-1,4-dihidropiridina-3-carboxi lato de 2-[n-(1,2-benzisotiazolil-3(2h) ona-1,1-dioxido]etilo.
DE69929124D1 (de) Anwendungsspezifische Kodierung von medizinischen Instrumente zur Einführung in einen Patientenkörper

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231